Why EMA Phased Review Could Transform GMP Submission Planning
The European Medicines Agency announced on July 7, 2026 that it had begun a phased assessment of daraxonrasib under its evolving regulatory framework. Unlike the traditional centralized marketing authorization process, the Committee for Medicinal Products for Human Use (CHMP) will evaluate quality, nonclinical, and clinical data as each section becomes available instead of waiting for a complete application.
Although the review focuses on a medicine for metastatic pancreatic cancer, its broader significance lies in the regulatory process itself. This approach demonstrates how the EMA intends to assess high-priority medicines more efficiently while maintaining the same standards for quality, safety, and efficacy.
How EMA Phased Review Is Reshaping CMC and Validation Readiness
The phased review model changes how pharmaceutical companies prepare for regulatory submissions. Instead of waiting until every module is complete, critical quality documentation may need to be ready much earlier in the development process.
As a result, CMC packages, stability data, and process validation activities could be completed earlier, requiring closer coordination between QA, Validation, Manufacturing, and Regulatory Affairs teams throughout development.
Why GMP Documentation Matters More Under EMA Phased Review
The accelerated assessment pathway does not reduce regulatory expectations. Instead, it changes when regulators begin reviewing evidence.
According to the EMA, medicines entering the phased review pathway must satisfy the same quality, safety, and efficacy requirements as products assessed through the conventional process. Therefore, manufacturers cannot rely on additional preparation time after submitting a complete dossier.
This shift places greater emphasis on maintaining inspection-ready GMP documentation throughout development. Validation reports, manufacturing records, stability data, and supporting quality evidence may all need to reach regulatory standards earlier than companies have traditionally expected.
How the EU Pharma Reform Is Accelerating Regulatory Reviews
The daraxonrasib review comes as the European Union advances its pharmaceutical legislation reform to modernize the medicine approval process.
Under the proposed framework, the standard assessment period for centralized marketing authorization applications is expected to decrease from 210 to 180 days, while medicines with major public health importance could qualify for a 150-day review. Together with phased assessment, these changes signal a shift toward earlier and more integrated regulatory evaluation throughout product development.
Earlier Regulatory Engagement Is Becoming the New Standard in Europe
The first implementation of phased assessment offers an early indication of how regulatory engagement may evolve across Europe.
Companies developing therapies for serious diseases, rare conditions, or areas with significant unmet medical need should expect earlier interaction with regulators and earlier preparation of quality documentation. At the same time, quality systems, validation programs, digital documentation, and regulatory strategies will need to become more integrated throughout the product lifecycle.
Although the EMA has not announced a timeline for completing the daraxonrasib review, the initiative demonstrates a broader regulatory trend. Future submissions may depend not only on the quality of supporting evidence but also on how early organizations can prepare robust CMC documentation, validation packages, and GMP-compliant data for regulatory assessment.
As regulatory expectations continue to shift toward earlier submission readiness, pharmaceutical teams should ensure their qualification, validation, and GMP documentation strategies evolve accordingly. Zamann Pharma Support’s Qualification and Validation for GMP-Regulated Systems service helps organizations build inspection-ready validation frameworks and compliant quality documentation throughout the entire system lifecycle.
Source: Pharmtech.Com